- Home
- CGBD vs XNCR Comparison
CGBD vs XNCR Comparison
Compare CGBD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGBD | XNCR |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.2M | 881.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CGBD | XNCR |
|---|---|---|
| Price | $10.96 | $11.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $12.92 | ★ $22.33 |
| AVG Volume (30 Days) | 598.3K | ★ 682.9K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.42% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.80 | $4.80 |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $10.64 | $6.92 |
| 52 Week High | $14.32 | $18.69 |
Technical Indicators
Market Signals| Indicator | CGBD | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 43.34 |
| Support Level | $10.68 | $11.02 |
| Resistance Level | $12.17 | $13.28 |
| Average True Range (ATR) | 0.29 | 0.78 |
| MACD | -0.10 | -0.21 |
| Stochastic Oscillator | 11.05 | 28.45 |
Price Performance
Historical ComparisonAbout CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.